EUVIMEDEUVIMED entdecken
Multizentrische Studie

Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country

Alessandra Borba Anton de Souza iD, Carlos Barrios iD, Rafaela Gomes de Jesus iD, Tomas Reinert iD, Juliana Giacomazzi iD, Daniela D Rosa, Eduardo Cronemberger iD, Gustavo Werutsky iD, José Bines iD, Geraldo Silva Queiroz, Vladmir Cordeiro de Lima iD, Ruffo Freitas-Junior iD und 19 weitere

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00337 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Alessandra Borba Anton de Souza und 30 weiteren Autor:innen. Beteiligte Einrichtung: CAPES Research Fellowship, Postgraduate Program, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Bra…. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing, Germ-Line Mutation, Healthcare Disparities. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Low rates of germline genetic testing (GGT) for breast cancer (BC) have been reported globally, with limited data from low- and middle-income countries (LMICs). In this study, we used real-world data to assess the GGT rate for BC in an LMIC and identified barriers to its use. METHODS We analyzed 2,974 newly diagnosed patients with BC from the AMAZONA III study, the largest Brazilian multicenter, prospective BC cohort. GGT rates were determined for the entire cohort and the high-risk hereditary BC group (HR), defined by the National Comprehensive Cancer Network criteria, between 2019 and 2020. Barriers to GGT performance associated with patient characteristics and health care systems were identified using multivariable Poisson regression model. Values of P < .05 were considered significant. RESULTS In the AMAZONA III cohort, 1,476 (49%) were classified as HR. Genetic counseling was recommended for 521 patients (35% of HR), and 282 (19%) underwent GGT. Notably, 97% of patients with HR treated within the public health care systems and 56% in the private system did not undergo GGT. Age, education, occupation, monthly income, availability of onsite genetic counseling, and treatment at a teaching center were factors associated with GGT uptake ( P < .05). Of those tested, 50 (17%) harbored a germline pathogenic or likely pathogenic variant. CONCLUSION Only 9% of this robust Brazilian BC cohort underwent GGT, highlighting a considerable gap from the current recommendation to test all patients with BC under age 65 years. GGT is underused by patients with HR in both public and private health care systems, with those in the public system being more affected. The disparities and barriers identified emphasize the need for educational interventions and enhanced access to GGT. Prioritizing GGT is critical to improving BC outcomes in LMICs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenetic TestingGerm-Line MutationHealthcare DisparitiesHumansFemaleMiddle AgedAdultBrazilProspective StudiesAged

Autor:innen und Institutionen

  • CAPES Research Fellowship, Postgraduate Program, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
  • Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), Porto Alegre, Brazil.
  • Oncoclinicas Group, Porto Alegre, Brazil.
  • Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias do Sul, Brazil.
  • Serviço de Oncologia Hospital Moinhos de Vento, Porto Alegre, Brazil.

ORCID-Profile: Alessandra Borba Anton de Souza, Carlos Barrios, Rafaela Gomes de Jesus, Tomas Reinert, Juliana Giacomazzi, Eduardo Cronemberger, Gustavo Werutsky, José Bines, Vladmir Cordeiro de Lima, Ruffo Freitas-Junior, Heloisa Resende, Susanne Crocamo, Vanessa Dybal, Diocesio Alves Pinto de Andrade, Alessandra Menezes Morelle, Carlos Alberto Sampaio Filho, Max Mano, Martina Lichtenfels, Sergio D Simon

Zitieren

APA

Souza, A. B. A., Barrios, C., de Jesus, R. G., Reinert, T., Giacomazzi, J., Rosa, D. D., Cronemberger, E., Werutsky, G., Bines, J., Queiroz, G. S., Cordeiro de Lima, V., Freitas-Junior, R., Couto Filho, J. D., Emerenciano, K., Resende, H., Crocamo, S., Van Eyll, B., Neron, Y., Dybal, V., …, & Fay, A. P. (2025). Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country. JCO Global Oncology. https://doi.org/10.1200/go-24-00337

Vancouver

Souza ABA, Barrios C, de Jesus RG, Reinert T, Giacomazzi J, Rosa DD, et al. Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country. JCO Global Oncology. 2025. doi:10.1200/go-24-00337

BibTeX
@article{Souza2025,
  author = {Souza, Alessandra Borba Anton de and Barrios, Carlos and de Jesus, Rafaela Gomes and Reinert, Tomas and Giacomazzi, Juliana and Rosa, Daniela D and Cronemberger, Eduardo and Werutsky, Gustavo and Bines, José and Queiroz, Geraldo Silva and Cordeiro de Lima, Vladmir and Freitas-Junior, Ruffo and Couto Filho, José d'Oliveira and Emerenciano, Karla and Resende, Heloisa and Crocamo, Susanne and Van Eyll, Brigitte and Neron, Yeni and Dybal, Vanessa and Lazaretti, Nicolas Silva and Costamilan, Rita de Cassia and Andrade, Diocesio Alves Pinto de and Mathias, Clarissa and Vacaro, Giovana Zerwes and Borges, Giuliano and Morelle, Alessandra Menezes and Sampaio Filho, Carlos Alberto and Mano, Max and Lichtenfels, Martina and Simon, Sergio D and Fay, Andre P},
  title = {Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00337}
}
Kostenlos starten →